Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and commercialize life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders. Soliris is Alexion's first marketed product, approved in the U.S., European Union and other countries as a treatment for all patients with PNH. Alexion is evaluating other potential indications for Soliris, and is pursuing development of other antibody product candidates in early stages of development.

(in thousands, except per share amounts)
FYE: 12/31	2009	2008	2007	2006
Net Revenues	$386,800	$259,099	$72,041	$1,558
Net Income	295,166	33,149	(92,290)	(131,514)
Earnings Per Share	3.26	0.39	(1.27)	(2.07)

(in thousands, except per share amounts)
	Second Quarter
FYE: 12/31	6/30/10	6/30/10
Net Revenues	$125,834	$92,256
Net Income	21,773	16,802
Earnings Per Share	0.24	0.19

Contact Name:
Contact Title:
Phone: